Sofia HCV: The Journey from Discovery to a Cure

Volume II
1. Auflage 2019
ISBN: 978-3-030-28400-8
Verlag: Springer International Publishing
Format: PDF
Kopierschutz: 1 - PDF Watermark

E-Book, Englisch, Band 32, 500 Seiten, eBook

Reihe: Topics in Medicinal Chemistry

Hepatitis C is a liver disease caused by the hepatitis C virus (HCV) and infects approximately 75 million individuals worldwide. It is also one of the major causes of liver cancer and liver transplants. The elucidation of the HCV genome, and the development of a whole cell system to study the virus spurred the search for novel direct acting antiviral drugs to cure this disease. This global effort culminated in the development of direct acting antiviral drugs that led to cure rates approaching 100% in all patient populations after only 8-12 weeks of therapy. These efforts resulted in one of the greatest achievements in public health and provides the potential for eliminating HCV as a major disease worldwide. This volume is aimed at a broad audience of academic and industrial scientists interested in the discovery and development of drugs to treat viral diseases and those interested in reading about one of the most unique accomplishments in biomedical research. The volume will provide a one of a kind reference work that highlights the many efforts, from the discovery of the HCV virus, to the invention of breakthrough medicines and their use in the real world to cure patients. It is the companion book to the volume "HCV: The Journey from Discovery to a Cure - Volume I".

Zielgruppe

Research

Autoren/Hrsg.

Sofia, Michael J.

Inhaltsverzeichnis

NS5A as a target for HCV Drug Discovery.- The Discovery and Development of Daclatasvir: An Inhibitor of the Hepatitis C Virus NS5A Replication Complex.- The Discovery of Ledipasvir (GS-5885): The Potent Once-Daily Oral HCV NS5A Inhibitor in the Single-Tablet Regimen Harvoni®.- The Discovery of Velpatasvir (GS-5816): The Potent Pan-Genotypic Once-Daily Oral HCV NS5A Inhibitor in the Single-Tablet Regimens Epclusa® and Vosevi®.-  Discovery of Elbasvir.- HCV NS5A as an Antiviral Therapeutic Target: From Validation to the Discovery and Development of Ombitasvir and Pibrentasvir as Components of IFN-Sparing HCV Curative Treatments.-  Evolution of HCV NS4B Inhibitors.- The Evolution of Clinical Trials for Hepatitis C.- The Clinical Development of Ledipasvir/Sofosbuvir (LDV/SOF, Harvoni®).- The Clinical Development of Sofosbuvir/Velpatasvir (SOF/VEL, Epclusa®).- The Clinical Development of Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX, Vosevi®).- Clinical Development of Viekira Pak to Mavyret.- Development of ZEPATIER®.- Real world effectiveness of DAA therapies.- The Benefit of Direct-Acting Antiviral HCV Cure Therapies.- Cure and Control: What Will It Take to Eliminate HCV?.- Perspectives on HCV Cure.

Über Autor(innen)

Michael J. Sofia, Ph.D. is currently Chief Scientific Officer and co-founder at Arbutus Biopharma, Inc., a company focused on the discovery and development of therapies to treat hepatitis B. He also holds a professorship at the Baruch S. Blumberg Institute and an Adjunct Professorship at the Drexel University School of Medicine. Previously, Mike Sofia was Senior Vice President of Chemistry and Senior Advisor at Gilead Sciences and was Sr. Vice President of Chemistry at Pharmasset, Inc until Pharmasset’s acquisition by Gilead in Jan 2012.Mike Sofia previously held research and research management positions at Bristol-Myers Squibb, Intercardia Research Labs (formerly Transcell Technologies) and  Eli Lilly & Co. He did his postdoctoral training in synthetic organic chemistry as an NIH fellow at Columbia University and received his Ph.D. in organic chemistry from the University of Illinois, Urbana-Champaign.  He earned his B.A. degree in chemistry from Cornell University.Mike has introduced numerous drugs into clinical development for the treatment of infectious diseases and inflammatory diseases. He is the principle inventor of sofosbuvir (Sovaldiâ and Harvoniâ) currently marketed as a treatment for the cure of HCV infection.  Mike is the recipient of numerous awards including the 2015 ACS Heroes of Chemistry Award, the Economist Magazine’s 2015 Innovation Award in Biosciences, the 2016 IUPAC-Richter Prize, the 2016 Lasker-Debakey Award in Clinical Medical Research and the 2017 Gertrude Elion Award from the International Society for Antiviral Research.